Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/908259/000149315222012308/form8-k.htm
June 2022
June 2022
June 2022
April 2022
April 2022
April 2022
April 2022
February 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/908259/000149315222012308/form8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Oncotelic Therapeutics, Inc..
Oncotelic Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Material Contracts, Statements, Certifications & more
Oncotelic Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: OTLCEvents:
CIK: 908259
Form Type: 8-K Corporate News
Accession Number: 0001493152-22-012308
Submitted to the SEC: Fri May 06 2022 6:10:34 AM EST
Accepted by the SEC: Fri May 06 2022
Period: Sunday, May 1, 2022
Industry: Pharmaceutical Preparations